Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Guardant Health a leading precision oncology company headquartered in Palo Alto, California, has announced the approval and issuance of a significant equity-based inducement compensation package for newly hired employees. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4), which permits certain equity awards to be issued outside of shareholder-approved equity incentive plans when they are used as a material inducement for employment.
Overview of the Announcement
The company disclosed that on April 21, 2026, the Compensation Committee of its Board of Directors approved the issuance of restricted stock units (RSUs) representing a total of 143,898 shares of common stock. These RSU awards were granted to 267 individuals who recently joined the organization as non-executive employees. The grant date for these awards was set as May 11, 2026.
These equity awards were issued under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan, commonly referred to as the “Inducement Plan.” This plan is specifically designed to offer equity compensation to individuals who are new hires or who are returning after a significant break in employment, with the goal of attracting and retaining talent in competitive labor markets.
Purpose of the Inducement Plan
The Inducement Plan plays a critical role in the company’s broader human capital strategy. It is not part of the company’s standard shareholder-approved equity compensation program. Instead, it is structured to provide flexibility in recruiting employees whose acceptance of employment may depend on the availability of equity-based incentives.
Under Nasdaq Listing Rule 5635(c)(4), companies listed on Nasdaq are allowed to grant equity awards without prior shareholder approval if those awards are used as a material inducement to employment. This rule is designed to help companies compete for talent, particularly in highly specialized industries such as biotechnology, pharmaceuticals, and precision medicine—fields in which Guardant Health operates.
By leveraging this rule, Guardant Health is able to offer competitive compensation packages that include stock-based incentives, thereby aligning new employees’ interests with those of shareholders from the beginning of their employment.
Details of the RSU Grants
The announced awards consist of restricted stock units, a form of equity compensation that provides employees with the right to receive shares of company stock after certain vesting conditions are met. In this case, the RSUs collectively represent 143,898 shares of Guardant Health common stock.
These RSUs were distributed among 267 new non-executive employees, meaning that the average grant size per employee varies depending on role, seniority, and hiring package. While the company has not disclosed individual award allocations, the aggregate figure reflects a broad-based hiring effort across multiple departments or functions.
Restricted stock units do not provide immediate ownership of shares. Instead, they represent a promise to issue shares in the future, subject to continued employment and other vesting requirements. Once vested, RSUs are typically converted into common stock and delivered to the employee.
Approval and Governance Process
The RSU grants were approved by the Compensation Committee of Guardant Health’s Board of Directors. This committee is responsible for overseeing executive and employee compensation programs, ensuring alignment with corporate strategy, market competitiveness, and regulatory compliance.
The approval date of April 21, 2026, indicates when the Compensation Committee formally authorized the inducement grants. The actual grant date—May 11, 2026—marks the point at which the RSUs were officially issued to employees.
This two-step structure is common in public companies, as it allows for administrative processing between approval and issuance while ensuring compliance with securities regulations and internal governance procedures.
Vesting Schedule and Conditions
The RSUs granted under this inducement program are subject to a time-based vesting schedule. Specifically, one-third of the shares underlying each RSU award will vest annually on the anniversary of the vesting commencement date.
This means that employees will gradually earn ownership of their awarded shares over a multi-year period, provided they remain continuously employed by Guardant Health. Full vesting will therefore occur over approximately three years, assuming uninterrupted service.
The vesting schedule serves several purposes:
First, it encourages employee retention by incentivizing recipients to remain with the company over time. If an employee leaves before the vesting milestones are reached, any unvested RSUs are typically forfeited.
Second, it aligns employee performance and commitment with long-term shareholder value creation. As employees’ equity stake grows over time, they become more directly invested in the company’s financial performance and strategic success.
Third, it provides a structured and predictable compensation framework, which is particularly important in high-growth, innovation-driven sectors like precision oncology.
Employment Conditions and Restrictions
The RSU awards are explicitly contingent upon continued employment. Each vesting installment is subject to the employee remaining actively employed with Guardant Health on the applicable vesting date. If an employee terminates employment—whether voluntarily or involuntarily—prior to a vesting date, any unvested portion of the award is generally forfeited.
In addition to employment conditions, the RSUs are governed by the terms and provisions of the Inducement Plan and the individual RSU award agreements signed by each employee. These documents outline the rights, obligations, and restrictions associated with the equity awards, including any provisions related to change in control, termination, or other corporate events.
Strategic Importance of Equity-Based Compensation
Equity compensation is a widely used tool in the biotechnology and healthcare technology sectors, where companies often compete intensely for highly specialized scientific, clinical, engineering, and commercial talent.
For a company like Guardant Health, which focuses on precision oncology solutions such as advanced blood and tissue diagnostic testing, attracting skilled employees is critical to maintaining innovation and market leadership. Offering RSUs helps ensure that new hires are financially aligned with the company’s long-term growth trajectory.
By granting equity rather than solely cash compensation, the company also conserves cash resources, which can be particularly important in research-intensive organizations that require sustained investment in clinical development, technology platforms, and regulatory expansion.
Regulatory Framework: Nasdaq Listing Rule 5635(c)(4)
The use of Nasdaq Listing Rule 5635(c)(4) is central to this announcement. This rule provides an exemption from the general requirement for shareholder approval of equity compensation plans when such awards are granted as a material inducement to employment.
The rule is commonly used by publicly traded companies to offer competitive hiring packages without needing to seek additional shareholder approval for each new hire. However, companies must still publicly disclose these grants and ensure that they are made under appropriate governance oversight.
In Guardant Health’s case, the Inducement Plan serves as the formal mechanism for issuing such awards, ensuring that all grants remain structured, transparent, and compliant with Nasdaq requirements.
Broader Implications for Workforce Growth
The issuance of RSUs to 267 new employees suggests ongoing expansion within the company’s workforce. While the announcement does not specify the departments or roles involved, inducement grants of this nature typically correspond to hiring across multiple functional areas, including research and development, clinical operations, data science, regulatory affairs, commercial operations, and corporate support functions.
Such hiring activity may indicate continued investment in scaling operations and advancing the company’s precision oncology platforms. As competition in the oncology diagnostics market continues to intensify, workforce expansion is often a key indicator of strategic growth initiatives.
Alignment With Long-Term Corporate Strategy
Guardant Health’s decision to grant inducement RSUs aligns with its broader strategy of innovation-driven growth. By linking employee compensation to equity performance, the company reinforces a culture of ownership and accountability.
Employees receiving RSUs effectively become stakeholders in the company’s future success, which can enhance motivation, productivity, and long-term commitment. This alignment between employee incentives and shareholder interests is a foundational principle in many high-growth technology and life sciences companies.
The announcement by Guardant Health, Inc. reflects a structured and strategic use of equity compensation to attract and retain new talent. Through the issuance of 143,898 RSUs to 267 non-executive employees under its 2023 Inducement Plan, the company continues to leverage Nasdaq Listing Rule 5635(c)(4) to remain competitive in hiring while maintaining compliance with regulatory standards.
The RSUs, which vest over a three-year period in equal annual installments, are designed to promote long-term employee retention and align new hires with the company’s strategic and financial objectives. As Guardant Health continues to expand its workforce and advance its precision oncology mission, such inducement programs play a key role in supporting its operational and growth priorities.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer.
